title: Somatic mutations at T-cell antigen receptor and glycophorin A loci in pediatric leukemia patients following chemotherapy: comparison with HPRT locus mutation.
abstract: Frequencies of somatic mutations in pediatric patients with leukemia were evaluated following intensive treatment at three different loci: the hypoxanthine-guanine phosphoribosyl transferase (HPRT), T-cell antigen receptor (TCR), and glycophorin A (GPA) gene. Thirty-two children with acute lymphoblastic leukemia (ALL), nine children with acute myelogenous leukemia (AML), and 20 age-matched healthy controls were included in the study of mutant frequencies (Mfs) at the HPRT and TCR loci. Among these patients and controls, individuals with heterozygous MN blood type, i.e., 14 children with ALL, three children with AML, and nine healthy controls, served for the further assessment of variant frequency (Vf) at the GPA locus. In ALL patients, geometric mean Mfs and Vfs at these loci were significantly higher than in healthy controls. The high Mf value at the HPRT locus persisted for up to 8 years after the end of chemotherapy. On the other hand, the Mf values at the TCR locus and Vf values at the GPA locus declined gradually with time. In AML patients, on the other hand, the geometric mean Mf only at the TCR locus was significantly higher than in the controls, albeit to a lesser degree than in ALL patients. These data suggest that anti-cancer therapy induces somatic mutations at various loci and that ALL patients are more susceptible to mutagenic intervention than are AML patients.
authors.affiliation: Department of Pediatrics, Kyoto University, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Hirota
authors.forename: M
authors.initials: M
authors.lastname: Kubota
authors.forename: S
authors.initials: S
authors.lastname: Adachi
authors.forename: A
authors.initials: A
authors.lastname: Okuda
authors.forename: Y W
authors.initials: YW
authors.lastname: Lin
authors.forename: R
authors.initials: R
authors.lastname: Bessho
authors.forename: Y
authors.initials: Y
authors.lastname: Wakazono
authors.forename: K
authors.initials: K
authors.lastname: Matsubara
authors.forename: K
authors.initials: K
authors.lastname: Kuwakado
authors.forename: Y
authors.initials: Y
authors.lastname: Akiyama
mesh_terms: D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D005260:Female; D006021:Glycophorins / Q000235:genetics*; D006801:Humans; D007041:Hypoxanthine Phosphoribosyltransferase / Q000235:genetics*; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000235:genetics; D008297:Male; D016296:Mutagenesis; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000235:genetics; D011948:Receptors, Antigen, T-Cell / Q000235:genetics*
chemical_list: D000970:Antineoplastic Agents; D006021:Glycophorins; D011948:Receptors, Antigen, T-Cell; D007041:Hypoxanthine Phosphoribosyltransferase